COST-EFFECTIVENESS OF GENOTYPE-DRIVEN ANTIPLATELET THERAPY FOR SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME

被引：0
|
作者：
Crespin, D. J. [1 ]
Federspiel, J. J. [1 ,2 ]
Biddle, A. K. [1 ]
Jonas, D. [2 ,3 ]
Stearns, S. C. [1 ]
Rossi, J. S. [2 ]
机构：
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[3] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72787-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A162 / A162
页数：1
相关论文
共 50 条
  • [1] Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis
    Crespin, Daniel J.
    Federspiel, Jerome J.
    Biddle, Andrea K.
    Jonas, Daniel E.
    Rossi, Joseph S.
    [J]. VALUE IN HEALTH, 2011, 14 (04) : 483 - 491
  • [2] COST-EFFECTIVENESS OF UNIVERSAL OR GENOTYPE DRIVEN USE OF AVAILABLE DUAL ANTIPLATELET STRATEGIES IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Lee, Soyon
    Dhamija, Asha
    Parsons, Katelyn
    King, Matthew
    Kaur, Rajbir
    Roberts, Matthew
    Coleman, Craig
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E483 - E483
  • [3] COST-EFFECTIVENESS EVALUATION OF GENOTYPE-GUIDED ANTIPLATELET THERAPY VERSUS UNIVERSAL NEW ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Jiang, M.
    You, J.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A20 - A20
  • [4] Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
    Kazi, Dhruv S.
    Garber, Alan M.
    Shah, Rashmee U.
    Dudley, R. Adams
    Mell, Matthew W.
    Rhee, Ceron
    Moshkevich, Solomon
    Boothroyd, Derek B.
    Owens, Douglas K.
    Hlatky, Mark A.
    [J]. ANNALS OF INTERNAL MEDICINE, 2014, 160 (04) : 221 - 232
  • [5] COST-EFFECTIVENESS OF UNIVERSAL VERSUS ASSAY-DRIVEN ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROME PATIENTS
    Coleman, C., I
    Limone, B. L.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A284 - A284
  • [6] Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome
    Coleman, Craig I.
    Limone, Brendan L.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2013, 112 (03): : 355 - 362
  • [7] Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome
    Jiang, Minghuan
    You, Joyce H. S.
    [J]. PHARMACOGENOMICS, 2016, 17 (07) : 701 - 713
  • [8] Cost-effectiveness analysis of genotype-guided antiplatelet therapy in patients with acute coronary syndrome and planned percutaneous coronary intervention.
    Lin, Fang-Ju
    Patel, Vardhaman
    Ojo, Olaitan
    Rao, Sapna
    Yu, Shengsheng
    Zhan, Lin
    Touchette, Daniel R.
    [J]. PHARMACOTHERAPY, 2012, 32 (10): : E300 - E300
  • [9] Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome
    Mathieu Pankert
    Jacques Quilici
    Thomas Cuisset
    [J]. Journal of Cardiovascular Translational Research, 2012, 5 : 41 - 51
  • [10] Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome
    Pankert, Mathieu
    Quilici, Jacques
    Cuisset, Thomas
    [J]. JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2012, 5 (01) : 41 - 51
12345